Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer

By afschroeder • August 22, 2025

Konecny GE, Davidson TM, Lebreton CL, Marsh LA, Chetram DK, Atkinson HJ, Larson MC, Oberg AL, Abdelaal N, Silverstein J, Jatoi A, Washburn A, Burton J, Dowdy S, Zhang L, Hallberg D, Velculescu VE, Slamon DJ, Wahner-Hendrickson AE. Phase II study of the efficacy and safety of palbociclib in patients with recurrent ovarian cancer. Int J Gynecol Cancer. 2025 Jul 28;35(10):102028. doi: 10.1016/j.ijgc.2025.102028. Epub ahead of print. PMID: 40839974.

Tags: CDK4/6 inhibitor, Cyclin-Dependent Kinases, Fellow, Hematology/Oncology, ovarian cancer, Palbociclib, Publications, targeted therapy

Oncofertility patterns after the overturn of Roe v. Wade

Baclig NV, Silverstein J, Shah V, Karlan B, Anand SR, Glaspy JA. Oncofertility patterns after the overturn of Roe v. Wade. J Natl Cancer Inst.[...]

Safety First

Moghanaki D, Gower A. Safety First. Int J Radiat Oncol Biol Phys. 2026 May 1;125(1):18. doi: 10.1016/j.ijrobp.2025.12.009. PMID: 42000358.

Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer

LeVee A, Hennessy MA, Idossa D, Leon-Ferre RA, Nanda R, McArthur H. Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer. Am Soc[...]